BioSyent Announces Appointment of New Director

The Board of Directors of BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased
to announce the appointment of Stephen Wilton to the Company's Board.


Mr. Wilton brings to BioSyent over 28 years of experience in the pharmaceutical
industry. A licensed pharmacist, Mr. Wilton earned a B.Sc. in Pharmacy from the
University of Toronto and started his career working as a pharmacist in
community and hospital pharmacy. After working in medical sales and marketing
positions at Eli Lilly Canada he joined AstraZeneca Canada where he enjoyed a
long and varied career. While at AstraZeneca, Mr. Wilton held leadership
positions in Marketing where as Executive Director he led a team managing a $300
million specialty product portfolio, as well as three other assignments as
Executive Director of Business Development, Executive Director of Pricing,
Reimbursment and Healthcare Solutions, and Director of Regulatory Affairs.


After his 17 year career at AstraZeneca, Mr. Wilton worked as Vice President of
Pharmacy Affairs for the Canadian Association of Chain Drug Stores representing
the interests of owners and pharmacists in the Canadian healthcare system.


Mr. Wilton, who also holds an MBA from York University (Schulich School of
Business) is presently President at Market Access Investment Advisors Inc.


BioSyent Inc. also announces the grant of 22,455 incentive stock options to
certain employees, officers and Directors of the Company. These incentive stock
options are excercisable at a price of $4.45 up to January 14, 2019.


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,626,195 shares issued and
outstanding. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals. 


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
[phone]
[e-mail]
www.biosyent.com